IDEXX Laboratories Inc.

360.20-1.98-0.55%Vol 531.23K1Y Perf -31.67%
May 16th, 2022 16:00 DELAYED
BID355.25 ASK431.52
Open359.60 Previous Close360.20
Pre-Market- After-Market360.88
 - -  0.68 0.19%
Target Price
612.17 
Analyst Rating
Moderate Buy 1.81
Potential %
69.95 
Finscreener Ranking
★+     43.54
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
     39.49
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★+     66.34
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
7.85 
Earnings Rating
Strong Sell
Market Cap30.26B 
Earnings Date
4th May 2022
Alpha0.01 Standard Deviation0.09
Beta1.11 

Today's Price Range

354.49362.98

52W Range

330.66706.95

5 Year PE Ratio Range

34.60105.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
5.89%
1 Month
-27.49%
3 Months
-26.99%
6 Months
-42.64%
1 Year
-31.67%
3 Years
44.33%
5 Years
123.67%
10 Years
756.19%

TickerPriceChg.Chg.%
IDXX360.20-1.9800-0.55
AAPL145.54-1.5700-1.07
GOOG2 295.85-34.4600-1.48
MSFT261.500.38000.15
XOM90.952.09002.35
WFC42.21-0.4300-1.01
JNJ178.081.23000.70
FB200.041.42000.71
GE74.63-0.4200-0.56
JPM118.26-0.8300-0.70
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.10
0.57
2.01
31.90
Leverage Ratio 3.50
ProfitabilityValueIndustryS&P 500US Markets
58.60
28.50
31.70
22.00
22.44
RevenueValueIndustryS&P 500US Markets
3.27B
38.98
12.01
11.57
Earnings HistoryEstimateReportedSurprise %
Q01 20222.252.270.89
Q04 20211.671.8913.17
Q03 20211.882.037.98
Q02 20212.012.3416.42
Q01 20211.722.3536.63
Q04 20201.432.0140.56
Q03 20201.421.6919.01
Q02 20201.201.7243.33
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.55-38.00Negative
9/2022 QR2.27-6.58Negative
12/2022 FY8.24-12.80Negative
12/2023 FY10.33-5.58Negative
Next Report Date-
Estimated EPS Next Report2.25
Estimates Count6
EPS Growth Next 5 Years %19.00
Volume Overview
Volume531.23K
Shares Outstanding84.01K
Shares Float74.23M
Trades Count19.36K
Dollar Volume192.46M
Avg. Volume810.31K
Avg. Weekly Volume972.56K
Avg. Monthly Volume849.43K
Avg. Quarterly Volume608.93K

IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 360.2 per share at the end of the most recent trading day (a -0.55% change compared to the prior day closing price) with a volume of 531.23K shares and market capitalization of 30.26B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 9300 people. IDEXX Laboratories Inc. CEO is Jonathan J. Mazelsky.

The one-year performance of IDEXX Laboratories Inc. stock is -31.67%, while year-to-date (YTD) performance is -45.3%. IDXX stock has a five-year performance of 123.67%. Its 52-week range is between 330.66 and 706.95, which gives IDXX stock a 52-week price range ratio of 7.85%

IDEXX Laboratories Inc. currently has a PE ratio of 42.50, a price-to-book (PB) ratio of 47.56, a price-to-sale (PS) ratio of 9.24, a price to cashflow ratio of 41.90, a PEG ratio of 2.32, a ROA of 30.67%, a ROC of 41.80% and a ROE of 112.72%. The company’s profit margin is 22.44%, its EBITDA margin is 31.70%, and its revenue ttm is $3.27 Billion , which makes it $38.98 revenue per share.

Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.25 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Moderate Buy (1.81), with a target price of $612.17, which is +69.95% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

IDEXX Laboratories Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.64, ATR14 : 20.15, CCI20 : -77.57, Chaikin Money Flow : -0.11, MACD : -42.55, Money Flow Index : 17.90, ROC : -19.66, RSI : 28.99, STOCH (14,3) : 22.60, STOCH RSI : 0.97, UO : 39.81, Williams %R : -77.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $3 189 519), Brian P. Mckeon (Sold 45 535 shares of value $28 485 272 ), Bruce L. Claflin (Option Excercise at a value of $307 898), Daniel M. Junius (Option Excercise at a value of $416 670), Daniel M. Junius (Sold 4 902 shares of value $2 981 273 ), Giovani Twigge (Option Excercise at a value of $7 556 014), Giovani Twigge (Sold 40 590 shares of value $28 341 797 ), James F. Polewaczyk (Option Excercise at a value of $678 500), James F. Polewaczyk (Sold 14 595 shares of value $8 527 691 ), Jonathan J. Mazelsky (Option Excercise at a value of $0), Jonathan J. Mazelsky (Sold 6 000 shares of value $4 051 262 ), Jonathan W. Ayers (Option Excercise at a value of $2 652 567), Jonathan W. Ayers (Sold 32 342 shares of value $17 657 279 ), Kathy V. Turner (Option Excercise at a value of $793 175), Kathy V. Turner (Sold 18 852 shares of value $11 033 724 ), M. Anne Szostak (Sold 2 400 shares of value $1 649 540 ), Michael J. Lane (Option Excercise at a value of $802 037), Michael J. Lane (Sold 6 494 shares of value $4 491 536 ), Nimrata Hunt (Option Excercise at a value of $174 085), Nimrata Hunt (Sold 538 shares of value $378 214 ), Sharon E. Underberg (Option Excercise at a value of $99 952)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (50.00 %)
5 (62.50 %)
6 (66.67 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
1 (11.11 %)
Hold
3 (37.50 %)
2 (25.00 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.81
Strong Buy
1.56
Strong Buy
1.50

IDEXX Laboratories Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

CEO: Jonathan J. Mazelsky

Telephone: +1 207 556-0300

Address: One IDEXX Drive, Westbrook 04092, ME, US

Number of employees: 9 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

58%42%

Bearish Bullish

64%36%

Bearish Bullish

61%39%

News

Stocktwits